Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer.
Bekric D, Neureiter D, Ablinger C, Dobias H, Beyreis M, Ritter M, Jakab M, Bischof J, Koller U, Kiesslich T, Mayr C.
Bekric D, et al. Among authors: kiesslich t.
Cancers (Basel). 2023 Mar 2;15(5):1569. doi: 10.3390/cancers15051569.
Cancers (Basel). 2023.
PMID: 36900361
Free PMC article.